MAPT and supranuclear palsy, progressive, 1: However, 1 st generation tau tracers have failed to identify PSP-type 4R pathology in vivo due to off-target binding in typical 4R aggregation sites such as the pallidum and overall low affinity to 4R tau [13–16].